Amino Acid Metabolism Disorders Treatment Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI4108
Amino Acid Metabolism Disorders Treatment Market size is projected to experience significant growth from 2019 to 2025.
Growing prevalence of amino acid metabolism disorders such as phenylketonuria and maple syrup urine will stimulate the global amino acid metabolism disorders treatment business growth over the coming years. Amino acid metabolism disorders are inherited metabolic disorders that mostly occurs in childhood. According to the National Organization for Rare Disorders, phenylketonuria is a rare disorder and incidence ranges from one in 13,5000 to 19,000 newborns in the U.S. On the other hand, maple syrup urine is seen in one out of 185,000 infants worldwide. In Australia, nearly 25 babies are diagnosed with phenylketonuria every year.
Financial burden due to increasing cost of amino acid supplements along with patient non-compliance will decline the amino acid metabolism disorder treatment market growth over the coming years. The cost is estimated to be around 4,000 Euros per year in the UK. Additionally, lack of awareness of such disorders will negatively impact the growth of the market. Physiological stress, pain, inconvenience and risk of infections associated with repeated injections of phenylketonuria will also negatively impact the industry expansion.
Carglumic acid segment will witness significant growth during the forecast period. Carglumic acid is used in the treatment of hyperammonemia seen in individuals with deficiency of N-acetyl glutamate synthase. According to the U.S. National Institutes of Health data, approximately 30 newborns in the U.S. are diagnosed with hyperammonemia every year. Growing prevalence of hyperammonemia will spur the demand of carglumic acid over the analysis period.
Hospital pharmacies distribution channel segment will hold a significant share over the upcoming years. Hospital pharmacies generally stock a large number of medications and specialized devices and provide medication to the hospital inpatients. The growing burden of the genetic disorder will increase the number of hospitalization, thereby positively impacting the growth of hospital pharmacies.
The U.S. amino acid metabolism disorders treatment market will foresee significant growth due to numerous on-going clinical trials regarding amino acid metabolism disorder treatment and several acquisitions and mergers amongst the key players present in the country. Additionally, increasing investment in research and development activities will further spur the growth of the U.S. market.
India amino acid metabolism disorders treatment market is expected to grow at a significant pace owing to the increase in nutritional management activities. Furthermore, improvement in healthcare and laboratory testing facilities to diagnose such disorders will spur the demand for medications required to treat disorders. According to the U.S. National Institutes of Health data, the incidence of phenylketonuria in India is around 7 newborns per 100,000 births every year and is more prominent in South India. The growing prevalence of metabolism disorders is expected to grow further in the upcoming years leading to industry growth.
Some of the prominent market players involved in the global amino acid metabolism disorders treatment market are Pfizer, AMINO GmbH, Merck KGaA, GlaxoSmithKline PLC, Civentichem among others. Companies are focusing on research and development activities to introduce technically advanced solutions and treatments. For instance, in December 2018, AMINO GmbH invested around USD 4.7 million for construction of the new innovation center. This new facility provided AMINO with technologies and conditions to develop chemicals to advance clinical trial phase.
Amino Acid Metabolism Disorders Treatment Market by Indication, 2014-2025 (USD Million)
- Maple syrup urine disease
- Argininosuccinic acidemia
Amino Acid Metabolism Disorders Treatment Market by Product, 2014-2025 (USD Million)
- Folic Acid
- Vitamin B6 and B12
- Vitamin D
- Carglumic acid
- Sapropterin dihydrochloride
Amino Acid Metabolism Disorders Treatment Market by Distribution Channel, 2014-2025 (USD Million)
- Hospital pharmacies
- Retail pharmacies
- Online stores
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
- GlaxoSmithKline PLC
- Pfizer, Inc.
- AMINO GmbH
- Merck KGaA
- Recordati S.p.A.
- Koninklijke DSM N.V.
- Shine Star (Hubei) Biological Engineering Co., Ltd.
- KYOWA HAKKO BIO CO., LTD.
- Civentichem, LLC, Ltd.
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Benefits of Association
Data Coverage & Quality
GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.
Client Trust & Security
GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.
Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.